Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus
- Nieminen, M S
- Altenberger, J
- Ben-Gal, T
- Böhmer, A
- Comin-Colet, J
- Dickstein, K
- Edes, I
- Fedele, F
- Fonseca, C
- García-González, M J
- Giannakoulas, G
- Iakobishvili, Z
- Jääskeläinen, P
- Karavidas, A
- Kettner, J
- Kivikko, M
- Lund, L H
- Matskeplishvili, S T
- Metra, M
- Morandi, F
- Oliva, F
- Parkhomenko, A
- Parissis, J
- Pollesello, P
- Pölzl, G
- Schwinger, R H G
- Segovia, J
- Seidel, M
- Vrtovec, B
- Wikström, G
DOIAbstract
The intravenous inodilator levosimendan was developed for the treatment of patients with acutely decompensated heart failure. In the last decade scientific and clinical interest has arisen for its repetitive or intermittent use in patients with advanced chronic, but not necessarily acutely decompensated, heart failure. Recent studies have suggested long-lasting favourable effects of levosimendan when administered repetitively, in terms of haemodynamic parameters, neurohormonal and inflammatory markers, and clinical outcomes. The existing data, however, requires further exploration to allow for definitive conclusions on the safety and clinical efficacy of repetitive use of levosimendan
Add to ORKG